endometrial hyperplasia. Hyperplasia of endometrium: NOS cystic glandular-cystic polypoid
Conditions
Interventions
Intervention 1: Control group will be teated with progesterone therapy protocol of 20-80 mg daily based on the type of hyperplasia, 14 days from the day of 14th of the menstrual cycle for three period
Treatment - Drugs
Control group will be teated with progesterone therapy protocol of 20-80 mg daily based on the type of hyperplasia, 14 days from the day of 14th of the menstrual cycle for three periods.
Intervention group, beside receiving treatment of progestrone in control group , will be treated with metformin by dose of 1000 mg for the first 4 weeks,then follow by 2000 mg metformin in remain
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: In this randomized clinical trial of patients with endometrial hyperplasia admitted to Arash hospital, Tehran, Iran in 2014 were diagnosed by biopsy sample were recruited. Inclusion criteria: women aged 18 to 75 years old with endometrial biopsy confirmed by endometrial hyperplasia; no contraindications to treatment with metformin; creatinine clearance greater than 90ml / min; using the formula of Cockroft-Gault; normal hepatic markers hemoglobin level above 10; satisfactory condition; physically fit to participate in the study. Exclusion criteria: taking metformin within the past 6 months; impaired hepatic function tests, blood sugar is less than 65 and no more than 200; history of alcohol use disorder; history of vitamin B12; pregnancy; history of insulin therapy; body mass index less than 25.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of endometrial hyperplasia. Timepoint: befor treatment,3 months after start treatment. Method of measurement: Review of Pathology. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of the hepatic effects of metformin in the treatment of patients with Endometrial hyperplasia. Timepoint: start of treatment and 3 months after that. Method of measurement: blood sampling and liver tests measurements.;Reviews of metformin renal complications in the treatment of patients with Endometrial hyperplasia. Timepoint: start teatment and 3 months after that. Method of measurement: blood sampling and measuring hepatic function test.;Effect of metformin in reduce blood glocose. Timepoint: start treatment and 3 months after that. Method of measurement: blood sampling and Blood glucose measurement.;Effect of metformin on body mass index. Timepoint: start treatment and 3 months after that. Method of measurement: Measurement of height and weight and body mass index calculator. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNasim Zarifi
Tehran University of Medical Sciences
Outcome results
None listed